Latest filing published 19 Mar 2026 for Tarsus Pharmaceuticals, Inc., €259k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Aziz Mottiwala, listed as senior executive, appears in our data through filings on Tarsus Pharmaceuticals, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 10 September 2021 to 17 March 2026, the count stands at 18 filings.
The open-market record consists of 12 sales worth €1.5M, with no purchase. Outside the open market, there are 6 option exercises. In 2026 alone, the filings show no purchases and 1 sale.
The latest filing, published on 19 March 2026, reports an open-market sale of €259k in Tarsus Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations